Description

4,4',4'',4'''-((1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-Tetrayl)Tetrakis(Methylene))Tetrabenzoic Acid is a sophisticated macrocyclic ligand derivative, integrating a cyclam core with multiple benzoic acid functional groups. This molecular architecture is critical for creating high-affinity chelating agents, particularly for metal ions like gadolinium and copper, which are essential in advanced diagnostic and therapeutic applications. It is primarily required by researchers and manufacturers in the pharmaceutical, medical imaging, and radiopharmaceutical industries for developing next-generation contrast agents and targeted radiopharmaceuticals.

Application

• MRI Contrast Agent Precursor: Serves as a key intermediate for synthesizing gadolinium-based macrocyclic contrast agents, prized for their high kinetic stability and safety profile.
• Radiopharmaceutical Chelator: Used in the development of copper-64 or gallium-68 labeled compounds for Positron Emission Tomography (PET) imaging and targeted radiotherapy.
• Molecular Imaging Probe Development: Acts as a versatile scaffold for creating multimodal imaging probes that combine MRI with optical or nuclear imaging capabilities.
• Catalysis Research: Functions as a ligand for transition metal catalysts in specialized organic synthesis and polymerization reactions.
• Material Science: Employed in the synthesis of metal-organic frameworks (MOFs) or functional polymers with specific metal-binding sites.
• Chemical Sensor Fabrication: Utilized as a receptor component in sensors designed for selective metal ion detection in analytical chemistry.

Basic Information

Product Name	4,4',4'',4'''-((1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-Tetrayl)Tetrakis(Methylene))Tetrabenzoic Acid
CAS No.	1886010-85-0
Molecular Formula	C50H56N4O8
Molecular Weight	840.99 g/mol
Synonyms	1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid, tetrakis(4-carboxyphenyl) derivative; Cyclam-tetraacetic acid, tetrakis(4-carboxyphenyl)-; Tetrakis(4-carboxyphenyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid; TETRAKIS(4-CARBOXYBENZYL)-1,4,8,11-TETRAAZACYCLOTETRADECANE; DO3A-tetra(p-carboxybenzyl); Precursor for DO3A-based MRI agents; 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetrayltetrakis(methylene-4,1-phenylene)tetraacetic acid
EINECS	Contact for details

Quality Control

Our production of 4,4',4'',4'''-((1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-Tetrayl)Tetrakis(Methylene))Tetrabenzoic Acid adheres to stringent quality protocols suitable for pharmaceutical intermediate applications. Each batch undergoes comprehensive analytical testing, including HPLC for purity, NMR and MS for structural confirmation, and residual solvent analysis. We provide detailed Certificates of Analysis (COA) with every shipment, ensuring traceability and compliance with relevant guidelines for advanced chemical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). This compound may be hygroscopic (moisture-sensitive); therefore, the container should be kept tightly sealed when not in use to minimize exposure to atmospheric humidity.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 95.0%
Water Content (KF)	≤ 2.0%
Residual Solvents (GC)	Meets ICH guidelines
Heavy Metals	< 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.